The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Retrospective analysis of immune-related adverse events (irAE) in metastatic renal cell carcinoma (mRCC) patients treated with first-line ipilimumab and nivolumab (I+N).
 
Kunal Desai
Stock and Other Ownership Interests - Co-D Therapeutics
 
Lisa A. Rybicki
No Relationships to Disclose
 
Amanda Nizam
No Relationships to Disclose
 
Laura S. Wood
Consulting or Advisory Role - Eisai; EMD Serono; Merck
Speakers' Bureau - Bristol-Myers Squibb; Genentech/Roche; Merck; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; EMD Serono; Genentech/Roche; Merck; Pfizer
 
Kimberly D. Allman
Consulting or Advisory Role - AstraZeneca; Bayer; Exelixis
Speakers' Bureau - Amgen; Exelixis
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; Exelixis
 
Allison Martin
No Relationships to Disclose
 
Cassandra Calabrese
Consulting or Advisory Role - GlaxoSmithKline
Speakers' Bureau - Genzyme
 
Timothy D. Gilligan
Travel, Accommodations, Expenses - Dendreon
 
Shilpa Gupta
Stock and Other Ownership Interests - Nektar
Honoraria - AstraZeneca; Bristol-Myers Squibb; Exelixis; Janssen Oncology; Merck Sharp & Dohme; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Janssen Oncology
Research Funding - Astellas Medivation (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
 
Moshe Chaim Ornstein
Consulting or Advisory Role - Eisai; Exelixis; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Exelixis
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Exelixis